# Safety, Tolerability and PK of ATTO-3712 in Healthy Volunteers and Patients With Atopic Dermatitis

> **NCT07205081** · PHASE1 · RECRUITING · sponsor: **Attovia Therapeutics Inc** · enrollment: 72 (estimated)

## Conditions studied

- Normal Volunteers
- Atopic Dermatitis (AD)
- Atopic Eczema
- Atopic Eczema/Dermatitis (Non-Specific)

## Interventions

- **DRUG:** ATTO-3712
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07205081
- **Lead sponsor:** Attovia Therapeutics Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-22
- **Primary completion:** 2026-10
- **Final completion:** 2026-10
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2025-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07205081

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07205081, "Safety, Tolerability and PK of ATTO-3712 in Healthy Volunteers and Patients With Atopic Dermatitis". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT07205081. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*